Cambridge Solves GIPR Paradox in Obesity Drugs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Cambridge researchers found that GIPR agonists (like Mounjaro and Zepbound) reduce appetite by acting in the brainstem, while GIPR antagonists (like MariTide) work in the hypothalamus by removing a "brake" that limits how strongly the brainstem responds to fullness signals.
- The mouse study, published in Nature Metabolism, used genetically engineered mice with GIPR selectively removed from either the brainstem or hypothalamus to pinpoint which brain region each drug class targets.
- MariTide, which combines GIPR antagonism with GLP-1 receptor agonism, is currently in phase 3 clinical trials — the new findings help explain why this combination strategy is effective.
- GIPR antagonism could also enhance the effects of emerging amylin receptor-targeting medicines, suggesting the mechanism may strengthen multiple classes of obesity drugs beyond GLP-1 combinations.
- Dr. Jo Lewis, the study's first author from Cambridge's Institute of Metabolic Science, said the work "strengthens the idea that the brain is central to obesity treatment" — drugs are not acting simply on the gut or pancreas.
- The research was funded by the Medical Research Council and Wellcome.
Why it matters: For over a billion people living with obesity, this research clarifies why drugs like Mounjaro, Zepbound, and MariTide work despite targeting the same receptor in opposite directions — and opens a path to combination therapies that pair GIPR-targeting drugs with GLP-1 drugs like Wegovy and Ozempic for stronger weight loss.
Ask SkimNews
